New hope for transplant patients with devastating gut rejection?

NCT ID NCT05415410

Terminated Disease control Sponsor: VectivBio AG Source: ClinicalTrials.gov ↗

Summary

This study tested a drug called apraglutide for patients with a severe complication after a stem cell transplant called graft-versus-host disease (GVHD). It focused on patients whose gut GVHD did not improve with standard steroid treatment. The trial aimed to see if adding apraglutide to their current therapy was safe and could help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Instituto Portugues de Oncologia do Porto Francisco Gentil

Porto, 4200-072, Portugal
Martin Luther Universität Halle-Wittenberg

Halle, 06120, Germany
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
South Austin Medical Center

Austin, Texas, 78704, United States
Stanford Cancer Center

Stanford, California, 94305, United States
The Ohio State University

Columbus, Ohio, 43210, United States
Universitaetsklinikum Duesseldorf

Düsseldorf, 40225, Germany
University of Iowa

Iowa City, Iowa, 52242, United States
Universitätsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany
Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20249, Germany
Universitätsklinikum Köln (AoeR)

Cologne, 50937, Germany
Universitätsmedizin der Johannes Gutenberg - Universität Mainz

Mainz, 55131, Germany

Conditions

Explore the condition pages connected to this study.

GVHD